{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:24Z","timestamp":1787841324531,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"vor","delay-in-days":1105,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>Allogeneic stem cell transplantation (SCT) offers the best chance of cure and long-term survival for children with myelodysplastic syndromes (MDS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN AND SETTING:<\/jats:title>\n                    <jats:p>Retrospective analysis of pediatric patients with primary MDS treated with allogeneic SCT at a single institution treated between January 1993 and December 2008.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS:<\/jats:title>\n                    <jats:p>Of 16 consecutive children who received allogeneic SCT for treatment of MDS in our center, 14 patients met the criteria of MDS according WHO I and II criteria. The median age was 4.8 years (range, 1-14 years) and 64% were male. The median time from diagnosis to transplant was 6 months. MDS stage was refractory cytopenia (RC) in 9, refractory anemia with excess blasts (RAEB) in 5. Monosomy 7 was present in 35% of the patients. The majority of patients (11\/14) were conditioned with a busulfan-based myeloablative (MA) regimen with addition of low-dose of etoposide (30 mg\/kg). All but one received a bone marrow graft.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Nine patients achieved complete remission (CR), and seven remain alive. At a median follow-up of 3 years (range, 2-14 years) the OS and EFS was 57% (95%CI, 0.28-0.78). Cumulative EFS at 1 0 years was 43% (95% CI: 0.14\u20130.70). Relapse-related mortality was 21.4%; nonrelapse mortality (NRM) was 28.57%. All the survivors had etoposide in their conditioning regimen. Patients younger than 10 years had better survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.001). CONCLUSION: Children with MDs achieve encouraging OS and EFS following allogeneic SCT. A busulfan-based regimen with a lower dose of etoposide is an effective and less toxic regimen. The outcomes are best in younger patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.5144\/1658-3876.2011.121","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T11:42:57Z","timestamp":1405510977000},"page":"121-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome"],"prefix":"10.4103","volume":"4","author":[{"given":"Amal","family":"Al-Seraihy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhab","family":"Ayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Al-Nounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"El-Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Ahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Jefri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Belgaumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.5144\/1658-3876.2011.121_bb0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.1992.tb02980.x","article-title":"Myelodysplastic syndrome in childhood: population-based study of nine cases","volume":"81","author":"Hasle","year":"1992","journal-title":"Br J Hematol"},{"key":"10.5144\/1658-3876.2011.121_bb0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0889-8588(18)30334-4","article-title":"Experience in pediatric myelodysplastic syndromes","volume":"6","author":"Gadner","year":"1992","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.5144\/1658-3876.2011.121_bb0015","first-page":"258","article-title":"Diagnosis, classification, and cytogenetics of myelodysplastic syndromes","volume":"89","author":"Vallespi","year":"1998","journal-title":"Hematologica"},{"key":"10.5144\/1658-3876.2011.121_bb0020","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/sj.leu.2400842","article-title":"Molecular cytogenetics of childhood hematological malignancies","volume":"11","author":"Martinez-Climent","year":"1997","journal-title":"Leukemia"},{"key":"10.5144\/1658-3876.2011.121_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e3280128ce8","article-title":"Myelodysplastic and myeloproliferative disorders in children","volume":"19","author":"Hasle","year":"2007","journal-title":"Curr Opin Pediatr"},{"key":"10.5144\/1658-3876.2011.121_bb0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2402765","article-title":"A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases","volume":"17","author":"Hasle","year":"2003","journal-title":"Leukemia"},{"key":"10.5144\/1658-3876.2011.121_bb0035","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"104","article-title":"Childhood myelodysplastic syndrome","author":"Baumann","year":"2008"},{"key":"10.5144\/1658-3876.2011.121_bb0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.V100.2.427","article-title":"Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation","volume":"100","author":"Barnard","year":"2002","journal-title":"Blood."},{"key":"10.5144\/1658-3876.2011.121_bb0045","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pbc.20596","article-title":"Outcome of hemopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome","volume":"47","author":"Woodward","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.5144\/1658-3876.2011.121_bb0050","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2655::AID-CNCR23>3.0.CO;2-W","article-title":"Transient monosomy 7: a case series in children and review of literature","volume":"85","author":"Mantadakis","year":"1999","journal-title":"Cancer"},{"key":"10.5144\/1658-3876.2011.121_bb0055","first-page":"1269","article-title":"Intensive chemotherapy in childhood myelodysplastic syndrome","volume":"10","author":"Hasle","year":"1996","journal-title":"A comparison with results in acute myeloid leukemia. Leukemia"},{"key":"10.5144\/1658-3876.2011.121_bb0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2007.06958.x","article-title":"Pediatric myelodys-plastic syndromes and juvenile myelomonocytic leukemia: molecular classification and treatment options","volume":"140","author":"Niemeyer","year":"2008","journal-title":"Br J Haematol"},{"key":"10.5144\/1658-3876.2011.121_bb0065","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.20.2.434","article-title":"Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group","volume":"20","author":"Woods","year":"2002","journal-title":"J Clin. Oncol"},{"key":"10.5144\/1658-3876.2011.121_bb0070","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2002-11-3444","article-title":"Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7","volume":"102","author":"Kardos","year":"2003","journal-title":"Blood."},{"key":"10.5144\/1658-3876.2011.121_bb0075","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bmt.1704438","article-title":"Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience","volume":"33","author":"Yusuf","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.5144\/1658-3876.2011.121_bb0080","first-page":"43","article-title":"Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT)","volume":"35","author":"Trobaugh-Lotrario","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.5144\/1658-3876.2011.121_bb0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"key":"10.5144\/1658-3876.2011.121_bb0090","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2007-06-098020","article-title":"results of the cord blood transplantation study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies","volume":"112","author":"Kurtzberg","year":"2008","journal-title":"Blood"},{"key":"10.5144\/1658-3876.2011.121_bb0095","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bbmt.2009.04.010","article-title":"Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.5144\/1658-3876.2011.121_bb0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/blood.V69.4.1015.1015","article-title":"Total body irradiation and high dose etoposide: A new regimen for bone marrow transplantation for patients with advanced hematologic malignancies","volume":"69","author":"Blume","year":"1987","journal-title":"Blood"},{"key":"10.5144\/1658-3876.2011.121_bb0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1096-911X(20001001)35:4<403::AID-MPO2>3.0.CO;2-M","article-title":"Hematopoietic stem cell transplantation with a conditioning regimen of busulfan, cyclophos-phamide and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the Pediatric Blood and Marrow Transplant Consortiu","volume":"35","author":"Sandler","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"10.5144\/1658-3876.2011.121_bb0110","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/pbc.20758","article-title":"The Outcome of Children With Acute Myeloid Leukemia (AML) Post-Allogeneic Stem Cell Transplantation (SCT) Is Not Improved by the Addition of Etoposide to the Conditioning Regimen","volume":"47","author":"Ayas","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.5144\/1658-3876.2011.121_bb0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/08880010902976742","article-title":"Allogeneic transplantation for myelodysplastic in children; A Report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON)","volume":"26","author":"Arturo Munoz","year":"2009","journal-title":"Pediatric Hematology and Oncology;"},{"key":"10.5144\/1658-3876.2011.121_bb0120","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program","volume":"99","author":"Castro-Malaspina","year":"2002","journal-title":"Blood"},{"key":"10.5144\/1658-3876.2011.121_bb0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.2004.05354.x","article-title":"Children with myelodysplastic syndrome (MDS) and mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy","volume":"128","author":"Bader","year":"2005","journal-title":"Br J Haematol"},{"key":"10.5144\/1658-3876.2011.121_bb0130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/pbc.21146","article-title":"Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and mono-somy 7","volume":"50","author":"Skinner","year":"2008","journal-title":"Pediatr Blood Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838761150024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838761150024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201104030-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:58Z","timestamp":1787838598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201104030-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.5144\/1658-3876.2011.121","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}